+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptic Ulcer Medication Market by End User (Adult, Geriatric, Pediatric), Drug Type (H2 Receptor Antagonists, Mucosal Protectants, Proton Pump Inhibitors), Dosage Form, Distribution Channel - Global Forecast 2025-2030- Product Image
Peptic Ulcer Medication Market by End User (Adult, Geriatric, Pediatric), Drug Type (H2 Receptor Antagonists, Mucosal Protectants, Proton Pump Inhibitors), Dosage Form, Distribution Channel - Global Forecast 2025-2030- Product Image
New

Peptic Ulcer Medication Market by End User (Adult, Geriatric, Pediatric), Drug Type (H2 Receptor Antagonists, Mucosal Protectants, Proton Pump Inhibitors), Dosage Form, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6137908
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The management of peptic ulcer disease remains a critical priority in global healthcare, as evolving epidemiological factors and patient risk profiles underscore the need for robust therapeutic strategies. Patients experiencing gastric mucosal lesions often face significant pain, potential complications such as bleeding or perforation, and the burden of recurrent symptoms. In parallel, healthcare systems across mature and emerging markets must contend with the economic implications of hospital admissions, endoscopic interventions, and long-term medication regimens.

Against this backdrop, clinicians and payers are increasingly focused on optimizing treatment pathways that balance efficacy, safety, and cost. Advances in understanding Helicobacter pylori eradication protocols and the role of nonsteroidal anti-inflammatory drugs in ulcerogenesis have prompted updates to clinical guidelines, while novel delivery methods and formulation improvements aim to enhance patient adherence. Consequently, pharmaceutical developers and healthcare providers are collaborating more closely to ensure alignment between patient needs, regulatory requirements, and market access strategies.

This introduction establishes the urgent call to action for industry stakeholders, setting the stage for an in-depth examination of the transformative shifts, policy impacts, and segmentation analyses that define the contemporary peptic ulcer medication sphere.

Unprecedented Scientific, Regulatory, and Digital Health Transformations Reshaping the Peptic Ulcer Medication Ecosystem

The peptic ulcer medication landscape is undergoing a series of transformative shifts driven by scientific breakthroughs, regulatory evolution, and patient expectations. Rapid advances in pharmacogenomics are informing tailored treatment regimens, while real-world evidence from digital health platforms is reshaping the way clinicians monitor long-term outcomes. Regulatory bodies are responding by streamlining approval pathways for combination therapies and biosimilars, heightening competition and accelerating product lifecycles.

Concurrently, the rise of antimicrobial resistance has prompted calls for alternative strategies to manage Helicobacter pylori eradication, accelerating research into non-antibiotic adjuncts and targeted microbial therapies. Digital therapeutics and telemedicine are gaining traction as complementary tools for remote monitoring of ulcer healing and adherence tracking, particularly in regions with limited gastroenterology specialists. In addition, patient advocacy groups are amplifying the focus on quality-of-life metrics, influencing formulary decisions and reimbursement negotiations.

Together, these converging trends are not only redefining clinical practice but also challenging pharmaceutical organizations to innovate across the value chain, from R&D investment through to patient engagement and post-market surveillance.

Analyzing the Compounding Consequences of United States Tariff Adjustments on Peptic Ulcer Drug Supply Chains and Pricing Dynamics

The introduction of revised tariff structures by the United States in 2025 has had a pronounced effect on the supply chain economics of peptic ulcer medications. Raw material costs for active pharmaceutical ingredients sourced from global suppliers have increased, prompting manufacturers to reassess their procurement strategies and inventory buffers. Some companies have responded by diversifying sourcing to include regional API manufacturers, while others have negotiated long-term contracts to mitigate price volatility.

In parallel, elevated import duties have exerted upward pressure on wholesale acquisition costs, which in turn influenced pharmacy pricing and reimbursement discussions. Payers have been compelled to review formulary placements, favoring therapies with vertically integrated supply chains or locally manufactured formulations to contain patient copayments. Smaller generic producers, in particular, have faced margin compression, leading several to explore strategic alliances or seek regulatory incentives for domestic production.

The cumulative impact of these tariff adjustments underscores the importance of agile sourcing models, transparent cost modeling, and collaborative engagement with health authorities to secure favorable pricing concessions. Manufacturers capable of demonstrating supply chain resilience and cost efficiency are better positioned to maintain competitive advantage in the evolving regulatory environment.

In-Depth Analysis of End User Demographics, Drug Classifications, Dosage Forms, and Distribution Channels Driving Market Behavior

A nuanced view of market segmentation provides critical insights into how patient demographics and treatment categories drive demand and product innovation. Analysis based on end user demographics reveals distinct clinical considerations for adult patients, who often present with lifestyle-related ulcer risk factors, versus geriatric populations, which face higher susceptibility to complications and polypharmacy interactions, and pediatric cases where dosing precision and safety profiles are paramount. Within the drug type portfolio, the enduring role of H2 receptor antagonists spans specific agents such as cimetidine, famotidine, nizatidine, and ranitidine, each offering differentiated receptor selectivity and dosing regimens. In the protective agent category, bismuth subsalicylate and sucralfate serve as adjunct therapies enhancing mucosal defense, whereas proton pump inhibitors, including esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole, have become standard of care due to superior acid suppression. Synthetic prostaglandins like misoprostol continue to play a specialized role in NSAID-induced ulcer prevention. Dosage form preferences range from capsules that facilitate controlled release, injectables for acute hospital settings, oral suspensions offering pediatric dosing flexibility, to conventional tablets favored in outpatient therapy. Distribution channel analysis highlights the pivotal influence of hospital pharmacies in inpatient and procedural contexts, the expanding reach of online pharmacies catering to home delivery, and the enduring footprint of retail pharmacies in community-based care.

Regional Dynamics of Peptic Ulcer Therapies Across Americas, Europe Middle East & Africa, and Asia-Pacific Illustrating Diverse Growth Drivers and Challenges

Geographic dynamics play a pivotal role in shaping both access and adoption of peptic ulcer treatments. In the Americas, reimbursement frameworks and competitive generic markets have fostered robust cost-containment strategies, with regional manufacturing hubs supporting rapid distribution and localized pricing models. Meanwhile, Europe, the Middle East & Africa exhibit varying regulatory landscapes; European Union directives harmonize approval processes, while Middle Eastern nations often incentivize local production, and African markets grapple with infrastructural constraints and supply chain inefficiencies.

In Asia-Pacific, rapid economic growth and expanding healthcare infrastructure have driven increased utilization of advanced proton pump inhibitors and novel therapeutic combinations. Regional disparities in regulatory stringency result in a dual market of high-end branded therapies in developed Asia-Pacific economies and lower-cost generics in emerging nations. Cross-border trade agreements and international partnerships are increasingly critical as stakeholders seek to optimize distribution and reduce time to market across these diverse territories.

Profiling Leading Pharmaceutical Innovators and Emerging Biotech Challengers Shaping the Competitive Peptic Ulcer Medication Landscape

The competitive landscape of peptic ulcer medication encompasses multinational pharmaceutical leaders, specialized generic manufacturers, and biotechnology firms exploring next-generation solutions. Established players have expanded portfolios through targeted acquisitions, alliance formations, and incremental innovation in drug delivery systems. For instance, leading global firms have invested in extended-release formulations to improve patient adherence, while mid-tier companies focus on cost-effective generics to capture price-sensitive segments.

Strategic collaborations between pharmaceutical innovators and contract manufacturing organizations have streamlined development timelines and optimized manufacturing scale. Moreover, a growing number of biotech enterprises are exploring non-traditional modalities, such as microbiome-based therapies and vaccine candidates targeting Helicobacter pylori. These diverse corporate strategies underscore the importance of R&D agility, regulatory acumen, and global supply chain integration to maintain leadership in this evolving market.

Strategic Imperatives for Industry Leaders to Harness Innovation, Strengthen Supply Chains, and Advance Patient-Centric Peptic Ulcer Solutions

Industry leaders seeking to thrive in the peptic ulcer medication sector should prioritize investment in precision medicine approaches, including pharmacogenomic profiling to tailor treatment regimens and minimize adverse events. Establishing strategic partnerships with API suppliers in low-cost regions can mitigate the impact of tariff volatility while diversifying raw material sources enhances supply chain resilience. Stakeholders should also explore value-based pricing frameworks that align reimbursement with real-world patient outcomes, thereby fostering payer collaboration and reducing cost barriers.

Expanding digital health initiatives, such as remote adherence monitoring and patient education platforms, can differentiate product offerings and strengthen patient engagement. Companies are encouraged to integrate advanced analytics into post-market surveillance, enabling rapid identification of safety signals and facilitating regulatory compliance. Finally, targeted outreach to geriatric and pediatric care centers, supported by tailored formulation strategies, will address unmet needs in these critical segments and unlock new growth avenues.

Comprehensive Multi-Method Research Framework Integrating Primary Expert Interviews, Secondary Literature Review, and Supply Chain Analysis

This research employs a rigorous methodology combining qualitative and quantitative techniques to ensure robust and reliable findings. Primary research encompasses in-depth interviews with gastroenterologists, hospital pharmacists, regulatory experts, and industry executives, providing frontline perspectives on clinical practice, market access, and strategic priorities. Secondary research involves a comprehensive review of peer-reviewed journals, regulatory filings, and clinical trial registries to validate therapeutic trends and identify emerging treatment modalities.

Additionally, supply chain analyses were conducted through collaboration with manufacturing and logistics specialists, mapping the flow of active pharmaceutical ingredients and finished doses across key regions. Data triangulation techniques were applied to reconcile discrepancies between primary insights and published literature, while scenario modeling assessed the impact of tariff changes and regulatory updates. This multi-layered approach ensures a balanced, transparent, and actionable set of insights for stakeholders.

Synthesis of Transformative Insights, Segmentation Analysis, and Competitive Dynamics to Forge a Strategic Path Forward in Peptic Ulcer Therapeutics

The peptic ulcer medication market stands at a pivotal juncture, shaped by novel scientific discoveries, shifting policy landscapes, and evolving patient expectations. Key findings highlight the critical role of personalized medicine, the ongoing challenge of antimicrobial resistance, and the strategic importance of supply chain agility in light of tariff adjustments. Segmentation insights reveal diverse demands across end user demographics, drug classes, dosage forms, and distribution channels, while regional analyses underscore the necessity of tailored market access strategies.

Competitive intelligence demonstrates that both established pharmaceutical conglomerates and agile biotech startups are driving forward innovation, leveraging partnerships to accelerate development and market penetration. Actionable recommendations focus on precision medicine, digital health integration, and value-based pricing to sustain growth and improve patient outcomes. Together, these insights provide a strategic blueprint for stakeholders aiming to navigate complexities and capitalize on opportunities within the dynamic peptic ulcer therapeutics arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Adult
    • Geriatric
    • Pediatric
  • Drug Type
    • H2 Receptor Antagonists
      • Cimetidine
      • Famotidine
      • Nizatidine
      • Ranitidine
    • Mucosal Protectants
      • Bismuth Subsalicylate
      • Sucralfate
    • Proton Pump Inhibitors
      • Esomeprazole
      • Lansoprazole
      • Omeprazole
      • Pantoprazole
      • Rabeprazole
    • Synthetic Prostaglandins
      • Misoprostol
  • Dosage Form
    • Capsules
    • Injectable
    • Oral Suspension
    • Tablets
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of antibiotic-resistant Helicobacter pylori strains driving development of novel therapeutic regimens
5.2. Rapid market uptake of potassium-competitive acid blockers like vonoprazan in Asia-Pacific treatment protocols
5.3. Personalized peptic ulcer therapies guided by CYP2C19 genotyping to optimize proton pump inhibitor efficacy
5.4. Increasing investment in combination therapies incorporating probiotics to reduce peptic ulcer recurrence rates
5.5. Growth of over-the-counter proton pump inhibitor sales in emerging markets due to rising self-medication trends
5.6. Integration of digital health platforms for remote monitoring of peptic ulcer symptom progression and compliance
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peptic Ulcer Medication Market, by End User
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Peptic Ulcer Medication Market, by Drug Type
9.1. Introduction
9.2. H2 Receptor Antagonists
9.2.1. Cimetidine
9.2.2. Famotidine
9.2.3. Nizatidine
9.2.4. Ranitidine
9.3. Mucosal Protectants
9.3.1. Bismuth Subsalicylate
9.3.2. Sucralfate
9.4. Proton Pump Inhibitors
9.4.1. Esomeprazole
9.4.2. Lansoprazole
9.4.3. Omeprazole
9.4.4. Pantoprazole
9.4.5. Rabeprazole
9.5. Synthetic Prostaglandins
9.5.1. Misoprostol
10. Peptic Ulcer Medication Market, by Dosage Form
10.1. Introduction
10.2. Capsules
10.3. Injectable
10.4. Oral Suspension
10.5. Tablets
11. Peptic Ulcer Medication Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Peptic Ulcer Medication Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Peptic Ulcer Medication Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Peptic Ulcer Medication Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AstraZeneca PLC
15.3.2. Takeda Pharmaceutical Company Limited
15.3.3. Pfizer Inc.
15.3.4. Sanofi S.A.
15.3.5. Teva Pharmaceutical Industries Ltd.
15.3.6. Merck & Co., Inc.
15.3.7. Eisai Co., Ltd.
15.3.8. GlaxoSmithKline plc
15.3.9. Novartis AG
15.3.10. Mylan N.V.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PEPTIC ULCER MEDICATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PEPTIC ULCER MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PEPTIC ULCER MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PEPTIC ULCER MEDICATION MARKET: RESEARCHAI
FIGURE 24. PEPTIC ULCER MEDICATION MARKET: RESEARCHSTATISTICS
FIGURE 25. PEPTIC ULCER MEDICATION MARKET: RESEARCHCONTACTS
FIGURE 26. PEPTIC ULCER MEDICATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PEPTIC ULCER MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY CIMETIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY FAMOTIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY NIZATIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY RANITIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY BISMUTH SUBSALICYLATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY SUCRALFATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY SUCRALFATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY MISOPROSTOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY MISOPROSTOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PEPTIC ULCER MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES PEPTIC ULCER MEDICATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 116. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 117. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 118. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 119. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 120. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 121. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 124. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 125. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. CANADA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 134. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 135. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 136. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 137. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. MEXICO PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER MEDICATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 216. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 217. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 218. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 219. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 220. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 221. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 222. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 223. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 224. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 225. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. GERMANY PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 232. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 233. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 234. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 235. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 236. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 237. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 238. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 239. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. FRANCE PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 262. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 263. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 264. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 265. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 266. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 267. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 268. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 269. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 270. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 271. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. ITALY PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 278. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 279. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 280. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 281. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 282. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 283. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 286. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 287. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. SPAIN PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY SYNTHETIC PROSTAGLANDINS, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES PEPTIC ULCER MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA PEPTIC ULCER MEDICATION MARKET SIZE, BY MUCOSAL PROTECTANTS, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA PEPTIC ULCER MEDIC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Peptic Ulcer Medication market report include:
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.

Related Topics

Related Reports

Peptic Ulcer Treatment Drugs Market by Drug Class (Antibiotics, H2 Receptor Antagonists, Mucosal Protectants), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Dosage Form, End User, Product Type - Global Forecast 2025-2030 - Product Image

Peptic Ulcer Treatment Drugs Market by Drug Class (Antibiotics, H2 Receptor Antagonists, Mucosal Protectants), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Dosage Form, End User, Product Type - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Peptic Ulcer Drugs - Global Strategic Business Report - Product Image

Peptic Ulcer Drugs - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Peptic Ulcer Drugs Market by Product Type, Ulcer Type, Distribution Channel, and Region 2025-2033 - Product Image

Peptic Ulcer Drugs Market by Product Type, Ulcer Type, Distribution Channel, and Region 2025-2033

  • Report
  • 135 Pages
  • Global
From
Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Peptic Ulcer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 215 Pages
  • Global
From
Peptic Ulcer Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Peptic Ulcer Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.